

Market Snapshot (Updated at 8AM)

Indian Indices	Close	Net Chng.	Chng. (%)
Sensex	46973.54	529.36	1.14
Nifty	13749.25	148.15	1.09

Global Indices	Close	Net Chng.	Chng. (%)
DOW JONES	30199.87	70.04	0.23
NASDAQ COM.	12804.73	33.62	0.26
FTSE 100	6502.11	6.36	0.10
CAC 40	5522.01	5.58	0.10
DAX	13587.23	169.12	1.26
NIKKEI 225	26749.44	91.62	0.34
SHANGHAI	3388.79	8.68	0.26
HANG SENG	26447.34	64.42	0.24

Currency	Close	Net Chng.	Chng. (%)
USD / INR	73.55	0.22	0.29
USD / EUR	1.22	0.00	0.16
USD / GBP	1.36	0.00	0.02
USD / JPY	103.55	0.12	0.12

Precious Metals	Close	Net Chng.	Chng. (%)
Gold (USD)	1898.48	14.90	0.79
Silver	26.87	0.97	3.73

Energy	Close	Net Chng.	Chng. (%)
NYMEX Crude	48.17	0.06	0.12
Brent Crude	51.17	0.12	0.23
Natural Gas	2.29	0.22	8.90

Bond	Close	Net Chng.	Chng. (%)
10 Yrs G-Sec	5.89	0.03	0.42

Indian ADRs	Close	Net Chng.	Chng. (%)
Dr. Reddy's Lab	70.43	0.05	0.07
HDFC Bank	69.55	0.48	0.69
ICICI Bank	13.99	0.12	0.87
Infosys Ltd	16.60	0.01	0.06
Tata Motors	11.80	0.15	1.29
Vedanta Ltd	8.68	0.35	4.20
Wipro	5.60	0.02	0.36

Institutional Flow (In Crore) 24-12-2020

Institution	Purchase	Sale	Net
FII	5316.24	4090.55	1225.69
DII	3456.22	5354.14	1897.92

Key Contents

- ⇒ [Market Outlook/Recommendation](#)
- ⇒ [Today's Highlights](#)
- ⇒ [Global News, Views and Updates](#)
- ⇒ [Links to important News highlight](#)

Top News for Today

- **Coal India:** Board accorded in-principle approval to venture into Aluminium Value Chain and Solar Power Value Chain.
- **Cadila Healthcare:** Zyclus Cadila submits Phase I and II clinical trial data of ZyCoV-D and has sought approval to begin phase III clinical trials.
- **NIIT:** Board approves buyback of 98.75 lakh equity shares of face value of Rs. 2 each. The buyback amounts to 6.97% of the total equity.
- **Westlife Development:** Royalty for FY21 and FY22 remains fixed at 4%. The company has opened four new stores post March 2020.
- **DLF:** DLF Cyber City Developers enters into a securities purchase agreement with Hines to acquire 51.8% stake in Fairleaf for a purchase consideration of approximately Rs 780 crore.
- **Advanced Enzymes Technologies:** To acquire 51% of equity share capital of SciTech Specialities, post which, SSPL will become a subsidiary of the company.
- **Lupin:** Gets tentative approval from the U.S. FDA for its Efinaconazole Topical Solution, 10%. It is used in the topical treatment of onychomycosis of the toenails.
- **Dish TV:** Gets demand notice worth Rs 4,164.05 crore from the Ministry of Information and Broadcasting. The said amount includes License Fee Payable and accrued interest thereon. The ministry has asked the company to remit the amount within a period of 15 days.
- **Asian Granito:** Expanding export network to over 120 countries from 100. Anti-China sentiments, reduction in gas prices and robust export orders from U.S., Europe, U.K. and the Middle-East are driving the export business in the current fiscal and it is likely to get further momentum in the coming months.
- **Biocon:** U.S. FDA informs Biocon Biologics of deferred action on the Biologics License Application (BLA) for MYL-14020, a proposed biosimilar to Avastin.
- **Balaji Telefilms:** Enters into collaboration with Ding Infinity to produce premium shows and films. The company will acquire a minimum of 55% stake for a cash consideration of not more than Rs 5 crore.
- **Central Bank Of India:** Has entered into a binding agreement to divest its entire equity stake of 64.40% i.e. 1.61 crore shares of face value of Rs 10 each in Cent Bank Home Finance, to Centrum Housing Finance, subject to approvals from regulatory authorities.
- **Indian Bank:** Has declared the NPA of Pratibha Industries and FEMC-Pratibha Joint Venture as fraud and reported them to the RBI. The two companies belonging to the Pratibha Group have total outstanding dues of Rs 574.66 crore.
- **Punjab & Sind Bank:** Has declared the NPA Account of Sintex Industries as fraud and reported to the RBI. The company has outstanding dues of Rs 294.49 crore having provisioning of Rs 147.25 crore.

Events of the Day

- **AGMs:** Gati Ltd, Zodiac Clothing, BF Utilities
- **Advanced Enzyme Technologies:** To meet InCred AMC and IIFL AMC on December 28.

Market in Detailed (Updated at 8AM)

Indian Indices	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	46973.54	529.36	1.14	0.18	7.18	25.64	13.30
Nifty	13749.25	148.15	1.09	0.06	6.93	24.42	12.56
BSE M Cap	17676.70	10.66	0.06	1.05	7.50	23.30	19.27
BSE S Cap	17675.53	103.51	0.59	0.76	8.02	21.94	32.06
Nifty MC 100	20475.75	35.80	0.18	1.79	7.58	24.07	21.50
BSE Auto	20316.54	103.37	0.51	2.13	2.77	17.16	11.27
BSE Capgoods	18390.16	8.52	0.05	1.15	9.05	36.68	8.55
BSE FMCG	12590.12	57.21	0.46	0.32	8.34	14.78	10.05
BSE Metal	11294.57	150.90	1.35	0.80	15.12	39.52	11.22
BSE Oil&Gas	13964.69	216.58	1.58	3.73	4.97	13.52	5.07
BSE Healthcare	21617.31	213.05	1.00	1.39	8.70	11.39	61.36
BSE Power	2049.99	7.66	0.38	1.83	3.62	27.13	7.97
BSE Realty	2360.81	10.78	0.45	2.09	18.61	42.98	5.66
BSE ConsDur	29205.81	275.46	0.95	0.58	11.67	27.50	16.53
BSE Bank	34926.54	608.39	1.77	1.07	4.39	46.65	5.08
BSE IT	24013.35	142.29	0.59	5.15	10.35	21.35	53.79

LME	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1898.48	14.90	0.79	0.90	6.19	0.90	25.67
Silver(\$/Ounce)	26.68	0.85	3.29	3.36	18.18	12.69	50.15
Aluminium	2025.75	27.35	1.37	0.72	2.78	18.99	13.14
Copper	7770.75	56.25	0.72	1.64	6.75	19.05	25.57
Zinc	2818.00	24.50	0.88	0.59	2.75	19.72	23.65
Lead	1948.75	0.75	0.04	4.57	2.97	6.33	0.74

Currency	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	73.55	0.22	0.29	0.05	0.62	0.49	3.10
USD Index	90.18	0.04	0.05	0.18	1.75	4.35	6.95
YUAN	6.53	0.01	0.17	0.29	0.74	4.30	6.99
GBP	1.36	0.00	0.02	0.69	1.76	5.63	3.39
EUR	1.22	0.00	0.16	0.25	2.40	4.69	9.05
YEN	103.55	0.12	0.12	0.22	0.73	1.88	5.15

Agro Commodities	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	125.95	1.40	1.12	0.51	8.67	11.61	9.68
Cotton	76.20	0.06	0.08	1.28	4.41	15.02	8.19
Sugar	14.90	0.07	0.47	1.50	0.93	11.44	4.49
Wheat	624.50	2.25	0.36	2.71	3.09	12.16	7.48
Soybean	1275.75	11.25	0.89	4.23	6.96	28.06	32.17

Global Indices	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	30199.87	70.04	0.23	0.34	1.10	11.14	5.91
Nasdaq	12804.73	33.62	0.26	0.31	5.87	17.33	43.02
S&P 500	3703.06	13.05	0.35	0.52	2.02	12.27	14.88
FTSE100	6502.11	6.36	0.10	0.75	1.74	11.29	14.81
CAC40	5522.01	5.58	0.10	0.49	0.88	16.75	8.42
DAX	13587.23	169.12	1.26	0.16	2.22	7.78	2.15
Mexico IPC	43372.20	225.10	0.52	2.15	2.78	18.56	1.78
Brazil Bovespa	117806.90	1170.70	1.00	0.04	7.31	21.44	1.68
Russian RTS	1378.36	0.03	0.00	1.72	5.83	18.13	11.04
Japan Nikkei	26749.44	91.62	0.34	0.13	0.39	13.77	12.21
Hang Seng	26447.34	64.42	0.24	0.18	0.82	13.84	5.07
Taiwan Index	14441.26	110.41	0.77	0.40	4.14	15.88	19.44
Shanghai Comp	3388.79	8.68	0.26	0.96	0.60	5.29	12.74
KOSPI	2824.17	18.96	0.68	1.93	8.62	24.01	29.03
Malaysia KLCI	1655.26	13.69	0.83	0.14	3.59	9.66	3.16
Jakarta Comp	6015.55	6.79	0.11	1.60	5.52	24.22	4.61
Philippine SE	7123.95	80.43	1.12	2.39	0.21	21.86	9.51
Thai Exch	1486.31	34.79	2.40	0.27	3.38	17.68	5.82

Freight	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	1366.00	4.00	0.29	5.00	14.12	18.06	25.32
Baltic Dirty	466.00	0.00	0.00	2.87	3.33	7.37	70.82
SG Dubai HY	0.92	0.07	8.24	16.46	26.03	201.10	250.82

Energy Markets	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	48.17	0.06	0.12	1.89	5.80	18.65	21.95
BRENT Crude	51.17	0.12	0.23	2.09	6.05	17.36	16.58
Natural Gas	2.29	0.22	8.90	15.04	19.31	32.51	15.07

Bond Markets	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	0.95	0.02	2.52	1.26	13.03	44.98	49.53
UK	0.26	0.00	0.00	3.21	19.18	35.98	66.58
Brazil	3.26	0.01	0.24	0.93	1.75	16.63	12.56
Japan	0.02	0.00	5.00	90.91	32.26	8.70	0.00
Australia	1.00	0.00	0.00	0.81	6.54	24.56	24.18
India	5.89	0.03	0.42	0.37	0.07	1.80	10.51
Switzerland	0.52	0.00	0.00	7.19	4.45	5.96	1.38
Germany	0.55	0.00	0.00	4.03	3.52	3.59	126.45

Taking global cues, Nifty is expected to open positive around 13,850 and likely to remain range-bound in the price band of 13,750-13,550.

The Nifty previous session ended 1.09% up at 13,749.25. It opened on a positive note and continued moving higher towards finishing off with a bullish body candle. Breaking out 13,800 is the immediate challenge for the Nifty bulls. On the flipside, intraday retracement may again find buyers on dips around 13,600 levels. Next support is placed around 13,550 levels.

On the Nifty hourly chart; both the leading indicators RSI and Stochastics recovered sharply pushing the benchmark index higher. Higher resistances are placed around 13,850 and 13,920 levels.

Nifty patterns on multiple time frames suggest; weekly candle pattern suggests the benchmark may challenge the critical resistance placed around 13,800. However, staying cautious on rise is advised.

The Bank Nifty previous session ended 1.74% up at 30,402.20. It might get into the trading range of 30,000-30,800.

Nifty Crucial Supports & Resistances-

Supports- 13600, 13550 Resistances- 13850, 13920

Open Positional Calls-

T+5 Positional Sell-

|Futures Segment| CONCOR Fut @ 378-380, TGT- 350, SL- above 395

T+5 Positional Sell-

|Futures Segment| SBIN Fut @ 261-263, TGT- 253, SL- above 268

T+1 Positional Buy-

|Cash Segment| M&M FIN @ 171-170, TGT- 178, SL- 166

- **Coal India:** Board accorded in-principle approval to venture into Aluminium Value Chain and Solar Power Value Chain. It has also approved creating Special Purpose Vehicles (SPVs), subject to approval from the Niti Aayog, DIPAM and after feasibility studies and business analysis are completed and financial viability is established for Solar Power Value Chain, New & Renewable Energy business vertical and an integrated aluminium complex, which will be a greenfield project by Central Coalfields.
- **Cadila Healthcare:** Zydus Cadila submits Phase I and II clinical trial data of ZyCoV-D and has sought approval to begin phase III clinical trials. Immunogenicity in Phase II clinical trial of ZyCoV-D in healthy subjects clearly established as also endorsed by the Independent Data Safety Monitoring Board. The company plans to initiate Phase III clinical trials in around 30,000 volunteers post necessary approvals.
- **NIIT:** Board approves buyback of 98.75 lakh equity shares of face value of Rs. 2 each. The buyback amounts to 6.97% of the total equity. Buyback price of Rs 240 per share is a 20% premium to Thursday's closing price.
- **Westlife Development:** Royalty for FY21 and FY22 remains fixed at 4%. The company has opened four new stores post March 2020. Over the last two quarters, the company has seen healthy recovery in business with dine-in building up rapidly, even as its convenience channels continue to grow.
- **DLF:** DLF Cyber City Developers enters into a securities purchase agreement with Hines to acquire 51.8% stake in Fairleaf for a purchase consideration of approximately Rs 780 crore. The transaction is expected to be consummated in the next quarter, subject to requisite closing conditions, post which Fairleaf will become a wholly-owned subsidiary of DLF Cyber City Developers. DCCDL already holds 48.2% stake in Fairleaf.
- **Advanced Enzymes Technologies:** To acquire 51% of equity share capital of SciTech Specialities, post which, SSPL will become a subsidiary of the company. The acquisition will be done for a cash consideration of Rs 31.26 crore and is likely to be completed by January 31, 2021. SSPL specialises in effervescent granules and tablets and the acquisition fits with the company's move to expand into the B2C business.
- **Lupin:** Gets tentative approval from the U.S. FDA for its Efinaconazole Topical Solution, 10%. It is used in the topical treatment of onychomycosis of the toenails. For the 12-months ending September 2020, it had annual sales of \$222.9 million in the U.S., as per IQVIA data.
- **Dish TV:** Gets demand notice worth Rs 4,164.05 crore from the Ministry of Information and Broadcasting. The said amount includes License Fee Payable and accrued interest thereon. The ministry has asked the company to remit the amount within a period of 15 days. The company also said that the amount is further subject to verification and audit and outcome of various court cases pending before the TDSAT, the Jammu & Kashmir Highcourt and the Supreme Court, in the matter of DTH License fee.
- **Asian Granito:** Expanding export network to over 120 countries from 100. Anti-China sentiments, reduction in gas prices and robust export orders from U.S., Europe, U.K. and the Middle-East are driving the export business in the current fiscal and it is likely to get further momentum in the coming months. Consolidated exports rose to around 17.6% of overall revenue in H1FY21 as compared to 13.8% in H1FY20. Inaugurated 15,000 square feet AGL Export House at Morbi to strengthen the company's international operations.
- **Biocon:** U.S. FDA informs Biocon Biologics of deferred action on the Biologics License Application (BLA) for MYL-14020, a proposed biosimilar to Avastin. The agency noted that an inspection of the manufacturing facility is required as part of the standard review process. However, due to restriction on travel, the agency is unable to conduct an inspection during the current review cycle.

- **Embassy Office Parks REIT:** Has completed the acquisition of Embassy TechVillage assets from the Embassy Sponsor, members of the Blackstone group and other selling shareholders for an enterprise value of Rs 9,782 crore (\$1.3 billion). The acquisition comprises 6.1 million square feet of completed area, 3.1 million square feet of under-construction area, of which 36% is pre-leased to JP Morgan, and two proposed 518-keys Hilton hotels within the overall ETV campus. With this acquisition, Embassy REIT's leasable area grows 28% to 42.4 million square feet.
- **Balaji Telefilms:** Enters into collaboration with Ding Infinity to produce premium shows and films. The company will acquire a minimum of 55% stake for a cash consideration of not more than Rs 5 crore. The acquisition is likely to be completed over the next six months.
- **Central Bank Of India:** Has entered into a binding agreement to divest its entire equity stake of 64.40% i.e. 1.61 crore shares of face value of Rs 10 each in Cent Bank Home Finance, to Centrum Housing Finance, subject to approvals from regulatory authorities. Aggregate cost of this divestment is about Rs 160 crore.
- **UltraTech Cement:** The company is considering a proposal to raise funds through the issue of 10,000 rated, listed, non-convertible, redeemable, unsecured NCDs worth Rs 10 lakh each, aggregating to Rs 1,000 crore on a private placement basis, on or after December 30, 2020.
- **Power Finance Corporation:** The Board of Directors in its meeting scheduled to be held on December 30 may consider a proposal for revision in limits for raising of resources i.e. Revised Market Borrowing program for the Financial Year 2020-21 through issuance of bonds, term loans from Banks/FIs, Commercial Paper etc. from domestic & international markets.
- **Reliance Industries:** The Company has entered into definitive agreements to acquire the shares held by IMG Singapore Pte. in IMG-R, for a cash consideration not exceeding Rs 52.08 crore. Post completion of acquisition, IMG-R will become a wholly-owned subsidiary of the company and will be rebranded.
- **Rupa Company:** Has submitted the Scheme of Arrangement between Oban Fashions, wholly-owned subsidiary of the company (Demerged Company) and Rupa Company Ltd. (Resulting Company) to be filed with the National Company Law Tribunal. The Scheme of Arrangement is submitted for demerger of the Demerged Undertaking of Oban Fashions into Rupa & Company on a going concern basis.
- **Indian Bank:** Has declared the NPA of Pratibha Industries and FEMC-Pratibha Joint Venture as fraud and reported them to the RBI. The two companies belonging to the Pratibha Group have total outstanding dues of Rs 574.66 crore.
- **Punjab & Sind Bank:** Has declared the NPA Account of Sintex Industries as fraud and reported to the RBI. The company has outstanding dues of Rs 294.49 crore having provisioning of Rs 147.25 crore.
- **TD Power Systems:** CRISIL has upgraded ratings on the bank facilities availed by the company. The Long-Term Rating of total bank loan facilities has been upgraded to A-/Stable from BBB+/Stable and Short-Term Rating has been upgraded to A2+ from A2.

Stocks, Equity Futures Climb; Dollar Edges Lower

U.S. equity futures pushed higher with most Asian stocks Monday after President Donald Trump signed a coronavirus stimulus package. The dollar ticked lower with Treasuries. S&P 500 contracts climbed as the White House confirmed that Trump had approved the combined \$2.3 trillion Covid-19 relief and government funding package. Shares advanced in Tokyo, Seoul and Hong Kong. The Bloomberg Dollar Spot Index dipped and Treasury yields climbed. Oil was little changed and gold rose. Alibaba Group Holding Ltd. slid in Hong Kong after its U.S.-listed shares tumbled the most ever on concern over China's inquiry into alleged monopolistic practices. The company Monday boosted its share buyback program to \$10 billion. Chinese regulators over the weekend ordered affiliate Ant Group Co. to return to its roots as a provider of payments services, a development that threatens to clip its growth. Elsewhere, the pound edged down after the U.K. last week clinched an historic Brexit trade deal with the European Union.

Oil Steadies with Virus Pessimism Balanced by U.S. Stimulus

Oil steadied in Asian trading -- after posting its first weekly loss since October -- as pessimism over a new strain of Covid-19 was balanced by the passage of a U.S. stimulus bill into law. Futures in New York traded near \$48 a barrel after sliding 1.8% last week. Tougher restrictions were extended to much of England to try and stem the virus mutation, while China suspended passenger flights to the U.K. American officials, meanwhile, warned of a post-Christmas surge of infections. Crude pared earlier losses after President Donald Trump signed the long-awaited bill containing \$900 billion of virus relief for Americans. Trump had previously expressed his displeasure with the bill, which is expected to boost energy demand in the world's largest economy, that Congress approved last week.

Orix to Buy Spanish Energy Firm Elawan for About \$965 Million

Orix Corp. agreed to buy Spain's Elawan Energy, the Japanese financial conglomerate's first deal to acquire a majority stake in an overseas renewable power company. Tokyo-based Orix is purchasing an 80% stake from Elawan's management and Spanish industrial company Acek, company spokeswoman Yuka Kanaoka said Monday. With an additional capital injection later, the deal is worth about 100 billion yen (\$965 million), she said. The transaction is expected to close in the second quarter of 2021, subject to receipt of regulatory approvals and satisfaction of customary closing conditions, Orix said in a statement. The acquisition will expand Orix's global renewable energy operations as it broadens a business portfolio that ranges from leasing to banking and real estate. Acek, which also owns car parts maker Gestamp Automocion SA, has been selling stakes in renewable assets.

Guangzhou Auto Plans to Increase Vehicle Sales By 10% Next Year

Guangzhou Automobile Group Co. is planning to increase its vehicle sales by 10% in 2021, following an expected drop this year. The Chinese automaker expects full-year vehicle sales in 2020 to be an estimated 2.04 million units, down 0.8% from 2019 levels, Guangzhou Automobile said in a statement to the Shanghai stock exchange after a board meeting held Friday. Overall automobile sales in China next year are expected to rise to 27.2 million units, according to a forecast jointly released by China Association of Automobile Manufacturers and Tianjin University at a conference earlier this month. Auto sales could fall about 2% this year, the association said.

Europe Starts Inoculating; Trump Signs Relief Bill

U.S. President Donald Trump signed a bill containing \$900 billion in pandemic relief. Top U.S. health officials warned of a post-Christmas surge in infections, as cases slowed amid scattered holiday reporting. A coordinated vaccination campaign was under way in Europe, just days after the European Union cleared a shot developed by Pfizer Inc. and BioNTech SE. The U.K. could clear AstraZeneca Plc's vaccine as early as this week. Concern about the mutated strain first detected in Britain grew in Asia, with Japan banning the entry of most foreigners through the end of January. Sydney will restrict crowds watching the New Year's Eve fireworks display as a Northern Beaches virus cluster grew to 126.

U.K. Poised to Clear AstraZeneca Shot as Need for Vaccines Grows

The U.K. is poised to approve the Covid-19 vaccine produced by AstraZeneca Plc and the University of Oxford, giving the country another powerful tool to fight the pandemic as concern mounts over rising infections. Britain's drug regulator could clear the shot for use as early as this week, according to a person familiar with the matter, who asked not to be identified because the deliberations are confidential. AstraZeneca Chief Executive Officer Pascal Soriot and U.K. health officials had previously said they hoped for approval by the end of the year. The go-ahead would come about three weeks after the U.K. became the first western country to begin vaccinations, using a shot from Pfizer Inc. and BioNTech SE that's been administered to more than 600,000 Britons. Still, virus cases have surged in Britain amid concern about a new strain of the coronavirus that officials have said is more contagious.

Trump Signs Virus Aid Bill After Panning \$600 Stimulus Checks

President Donald Trump signed a bill containing \$900 billion in pandemic relief, the White House said, triggering the flow of aid to individuals and businesses and averting the risk of a partial government shutdown on Tuesday. In addition to aid to stem the economic effects of the pandemic, the legislation Congress passed Monday also includes \$1.4 trillion in government spending to fund federal agencies through the end of the fiscal year in September. The government had been operating on temporary spending authority that expires after the end of the day Monday. The combined \$2.3 trillion package was the product of intense negotiations, from which Trump was largely absent until he surprised lawmakers of both parties by demanding bigger stimulus payments for individuals after the bill was already passed. Trump said in the statement announcing the signing that the GOP Senate had agreed to vote on increasing the \$600 individual payments and two other, unrelated matters dealing with social media and his unfounded allegations of voter fraud.

Auto / Auto Ancillaries

[Nexzu Mobility eyeing global market; in talks for e-cycle exports to US, UK](#)

[Renew vehicle papers by December 31 or face penalty](#)

[Mercedes says reduction in cess to go long way in expanding luxury car segment in India](#)

[Two-wheeler industry hopeful of growth in Q4 but wary of farmers' stir, Budget: HMSI](#)

Banking & Finance

[Global private banks ask FPI managers not to sell NRI clients' investments](#)

[Asset management firm in the works to tackle bad loans of PSU banks](#)

[PMC Bank money laundering case: ED summons Sanjay Raut's wife for questioning on December 29](#)

[2021: Banks brace for pandemic-hit corporates' bad loan woes, muted credit growth](#)

[PNB puts 3 stressed accounts up for sale](#)

[Ahead of DHFL voting, Oaktree fires fresh salvo against Piramal bid](#)

Oil & Gas

[Welspun Corp bags orders for more than Rs 6,000 crore to be executed through Q3 and Q4 of FY21](#)

Metals/Mining/Power

[India's crude steel output grows 3.5 percent to over 9 million tonne in November](#)

IT/Telecom/Media

[Reasonable spectrum pricing, forward movement on 5G among priorities for 2021: BIF](#)

FMCG/Retail/Textile/Food

[Wistron's iPhone factory in Kolar will be operational in 20 days, says Minister](#)

[Beverages market return to pre-covid growth](#)

[Lifestyle expects fashion retail to reach pre-pandemic level by second quarter of next fiscal](#)

[Prices of TV and appliances likely to go up by around 10% from January](#)

[Asus bets on offline retail, to add 1,000 retail points](#)

[Companies want separate 3% PLI incentives for PCB making](#)

Pharma/Fertilizers/Healthcare/Chemical

[AstraZeneca-Oxford Covid vaccine has 'winning formula': Chief executive](#)

[AstraZeneca's coronavirus vaccine has a 'winning formula', says drug major's chief executive](#)

[Hyderabad set to emerge as global hub for Covid-19 vaccine in 2021](#)

[India to play vital role in equitable distribution of COVID-19 vaccines around the world: Pharma industry](#)

Infrastructure/Cement/Real Estate

[L&T plans to hire 1,100 engineers across business verticals in 2021](#)

Analyst Certification:

We /I, Deepankar Saha & Jaydeb Dey Research Analyst(s) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the Financial Instruments of the Subject Company/companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report. Or at the time of Public Appearance. SMIFS does not have proprietary trades but may at a future date, may opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing. The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

Neither the Research Analysts nor SMIFS have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

For queries related to compliance of the report, please contact: -

Sudipto Datta, Compliance Officer

SMIFS Limited.

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5414 /91 33 6634 5414

Email Id.: compliance@smifs.com | Website: www.smifs.com